logo-loader
viewAmryt Pharma PLC

Amryt Pharma expands exclusive licence agreement for Lojuxta

Rory Nealon, chief operating officer at Amryt Pharma PLC (LON:AMYT), tells Proactive's Andrew Scott they've signed an agreement with Aegerion Pharmaceuticals Inc to significantly expand their exclusive licence agreement for Lojuxta into Russia and the Commonwealth of Independent States, as well as the non-EU Balkan States.

Nealon says there could be up to 450 additional patients in the countries covered by the agreement who could benefit from Lojuxta - which treats a rare life-threatening disorder that causes abnormally high levels of "bad" cholesterol.

Quick facts: Amryt Pharma PLC

Price: 125 GBX

AIM:AMYT
Market: AIM
Market Cap: £193.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Amryt Pharma well positioned to become 'global leader in...

Amryt Pharma PLC's (LON:AMYT) Rory Nealon talks Proactive London's Andrew Scott through their trading update for the nine months to the end of September 2019. It's a period in which Amryt completed the acquisition of Aegerion Pharmaceuticals Inc and saw the firm go from a single-product,...

on 5/11/19

2 min read